196 related articles for article (PubMed ID: 36212445)
1. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
Front Oncol; 2022; 12():946319. PubMed ID: 36212445
[TBL] [Abstract][Full Text] [Related]
2. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Fanale D; Incorvaia L; Badalamenti G; De Luca I; Algeri L; Bonasera A; Corsini LR; Brando C; Russo A; Iovanna JL; Bazan V
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925671
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.
Bian B; Fanale D; Dusetti N; Roque J; Pastor S; Chretien AS; Incorvaia L; Russo A; Olive D; Iovanna J
Oncoimmunology; 2019; 8(4):e1561120. PubMed ID: 30906655
[TBL] [Abstract][Full Text] [Related]
5. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
6. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
Billon E; Chanez B; Rochigneux P; Albiges L; Vicier C; Pignot G; Walz J; Chretien AS; Gravis G; Olive D
Front Immunol; 2021; 12():670827. PubMed ID: 33959132
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Incorvaia L; Rinaldi G; Badalamenti G; Cucinella A; Brando C; Madonia G; Fiorino A; Pipitone A; Perez A; Li Pomi F; Galvano A; Gristina V; Barraco N; Bono M; Bazan Russo TD; Toia F; Cordova A; Fanale D; Russo A; Bazan V
Ther Adv Med Oncol; 2023; 15():17588359231151845. PubMed ID: 36818688
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
10. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.
Matte I; Garde-Granger P; Bessette P; Piché A
Am J Cancer Res; 2019; 9(1):160-170. PubMed ID: 30755819
[TBL] [Abstract][Full Text] [Related]
11. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
12. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
13. BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
Li X; Xu Z; Cui G; Yu L; Zhang X
Onco Targets Ther; 2020; 13():215-224. PubMed ID: 32021268
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
[TBL] [Abstract][Full Text] [Related]
15. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
Eurich K; De La Cruz P; Laguna A; Woodman M; McAdams J; Lips E; Ebott J; DiSilvestro J; Ribeiro J; James N
Gynecol Oncol; 2023 Jul; 174():200-207. PubMed ID: 37224792
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.
Jin X; Du M; Wang Y; Wang Y; Lu Y; Xu C; Zhang X
J Ovarian Res; 2022 Dec; 15(1):134. PubMed ID: 36564848
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies.
Gorgulho J; Roderburg C; Heymann F; Schulze-Hagen M; Beier F; Vucur M; Kather JN; Laleh NG; Tacke F; Brümmendorf TH; Luedde T; Loosen SH
Int J Cancer; 2021 Sep; 149(5):1189-1198. PubMed ID: 33890289
[TBL] [Abstract][Full Text] [Related]
20. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
Cano CE; Pasero C; De Gassart A; Kerneur C; Gabriac M; Fullana M; Granarolo E; Hoet R; Scotet E; Rafia C; Herrmann T; Imbert C; Gorvel L; Vey N; Briantais A; le Floch AC; Olive D
Cell Rep; 2021 Jul; 36(2):109359. PubMed ID: 34260935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
